Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Gilead Sciences Inc buy gerihouse

Start price
€59.30
03.05.19 / 50%
Target price
€70.00
27.05.19
Performance (%)
1.57%
End price
€60.23
27.05.19
Summary
This prediction ended on 27.05.19 with a price of €60.23. The BUY prediction by gerihouse finished with a performance of 1.57%. gerihouse has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Gilead Sciences Inc 1.712% 1.712% -13.934% 10.110%
iShares Core DAX® 4.094% 3.543% 17.404% 20.326%
iShares Nasdaq 100 1.424% 0.512% 39.212% 55.365%
iShares Nikkei 225® -1.572% -4.633% 15.731% 2.146%
iShares S&P 500 1.822% 0.963% 30.396% 45.950%

According to gerihouse what are the pros and cons of Gilead Sciences Inc for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Future proof or reliable business model
Small cyclical dependencies
Cons

Comments by gerihouse for this prediction

In the thread Gilead Sciences Inc diskutieren
Prediction Buy
Perf. (%) 1.57%
Target price 70.000
Change
Ends at 27.05.19

Besser

Der amerikanische Biotechnologiekonzern Gilead Sciences, Inc. (ISIN: US3755581036, NASDAQ: GILD) wird eine Quartalsdividende von 0,63 US-Dollar je Aktie ausschütten. Die Zahlung für das zweite Quartal erfolgt am 27. Juni 2019 (Record date: 14. Juni 2019). Auf das Jahr hochgerechnet zahlt Gilead aktuell 2,52 US-Dollar an seine Aktionäre.

Beim derzeitigen Börsenkurs von 65,84 US-Dollar (Stand: 2. Mai 2019) ergibt sich eine aktuelle Dividendenrendite von 3,86 Prozent. Im Juni 2015 zahlte Gilead erstmals eine Dividende (0,43 US-Dollar). Seitdem wurde die Dividende viermal angehoben. Zuletzt gab Gilead im Februar 2019 eine Anhebung um 11 Prozent auf den aktuellen Betrag bekannt.

Gilead Sciences ist ein Biotechnologiekonzern, der Arzneimittel für verschiedene medizinische Bereiche erforscht, entwickelt und vermarktet. Neben Hepatitis konzentriert sich Gilead auf Medikamente zur Behandlung von HIV und Aids. Der Konzern erwirtschaftete im ersten Quartal des Fiskaljahres 2019 einen Umsatz in Höhe von 5,3 Mrd. US-Dollar im Vergleich zu 5,1 Mrd. US-Dollar im Vorjahr, wie am Donnerstag berichtet wurde. Dabei stand ein Ertrag von 1,98 Mrd. US-Dollar nach einem Ertrag von 1,54 Mrd. US-Dollar im Vorjahr in den Büchern.

Die Aktie liegt seit Anfang des Jahres 2019 an der Wall Street mit 4,40 Prozent im Plus und die aktuelle Marktkapitalisierung liegt bei 82,7 Mrd. US-Dollar (Stand: 2. Mai 2019).

Redaktion MyDividends.de



Prediction Buy
Perf. (%) 1.57%
Target price 70.000
Change
Ends at 27.05.19

(Vom Mitglied beendet)

Stopped prediction by gerihouse for Gilead Sciences Inc

buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€70.87
08.06.20
€65.00
04.11.21
-18.67%
05.11.21

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€70.51
18.05.20
€90.00
30.05.20
-4.08%
30.05.20

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€77.59
02.05.20
€85.00
16.05.20
-8.49%
16.05.20

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€78.80
20.04.20
€85.00
02.05.20
-1.54%
02.05.20

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€68.19
28.02.20
€85.00
20.04.20
15.56%
20.04.20

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€57.14
28.10.19
€70.00
09.11.19
2.28%
09.11.19

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€59.55
16.09.19
€65.00
28.10.19
-4.05%
28.10.19

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€71.09
03.10.17
€76.00
25.06.18
-12.90%
25.06.18

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€59.60
21.06.17
€72.16
30.08.17
21.12%
30.08.17

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€80.73
29.04.16
€100.00
28.03.17
-20.63%
28.03.17

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€75.79
08.02.16
€100.00
28.04.16
14.98%
28.04.16

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€99.55
04.11.15
€115.00
29.01.16
-22.56%
29.01.16

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€88.52
12.10.15
€100.00
27.10.15
12.97%
27.10.15

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€86.75
24.08.15
€100.00
21.09.15
9.95%
21.09.15

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€93.74
04.05.15
€110.00
29.06.15
11.35%
29.06.15

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€85.69
05.02.15
€100.00
18.03.15
7.04%
18.03.15

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€81.88
08.09.14
€95.00
28.01.15
12.25%
28.01.15

Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand